Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp.'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach.

Gritstone launched in October 2015 with a genomics and proteomics platform for identifying patient-specific neoantigens produced by tumors as they mutate. The company is studying samples from patients who receive checkpoint inhibitors to identify which combinations of neoantigens can induce an immune response. The research also will be used to develop a predictive model for creating personalized neoantigen vaccines...